Abstract
Background: Recent studies have identified the correlation between dementia and certain vocal features, such as voice and speech changes. Vocal features may act as early markers of Alzheimer's disease (AD). Despite being present in non-pathological senescence and Mild Cognitive Impairment, especially in its amnesic subtype (aMCI), these voice- and speech-related symptoms are the first signs of AD. The purpose of this study is to verify whether these signs are related to deficits in lexical access, which appear early in AD.
Method: Anomic deficits in persons with MCI and AD are assessed through tests on verbal memory, denomination by confrontation, and verbal fluency. In addition, an acoustic analysis of speech is conducted in a reading task to identify the acoustic parameters associated with the groups analyzed, and their relation to the degree of anomic impairment observed in each one of them.
Results and Conclusions: The results show a direct relationship between the different acoustic parameters present in AD and the verbal fluency tests results.
Keywords: Alzheimer's disease, mild cognitive impairment, anomic aphasia, acoustic analysis, speech, memory.
Current Alzheimer Research
Title:Voice Markers of Lexical Access in Mild Cognitive Impairment and Alzheimer's Disease
Volume: 15 Issue: 2
Author(s): Juan J.G. Meilan*, Francisco Martinez-Sanchez, Juan Carro, Nuria Carcavilla and Olga Ivanova
Affiliation:
- Faculty of Psychology, University of Salamanca, Campus Ciudad Jardin-Avenida de la Merced 109-131, 37005 Salamanca,Spain
Keywords: Alzheimer's disease, mild cognitive impairment, anomic aphasia, acoustic analysis, speech, memory.
Abstract: Background: Recent studies have identified the correlation between dementia and certain vocal features, such as voice and speech changes. Vocal features may act as early markers of Alzheimer's disease (AD). Despite being present in non-pathological senescence and Mild Cognitive Impairment, especially in its amnesic subtype (aMCI), these voice- and speech-related symptoms are the first signs of AD. The purpose of this study is to verify whether these signs are related to deficits in lexical access, which appear early in AD.
Method: Anomic deficits in persons with MCI and AD are assessed through tests on verbal memory, denomination by confrontation, and verbal fluency. In addition, an acoustic analysis of speech is conducted in a reading task to identify the acoustic parameters associated with the groups analyzed, and their relation to the degree of anomic impairment observed in each one of them.
Results and Conclusions: The results show a direct relationship between the different acoustic parameters present in AD and the verbal fluency tests results.
Export Options
About this article
Cite this article as:
Meilan J.G. Juan*, Martinez-Sanchez Francisco, Carro Juan, Carcavilla Nuria and Ivanova Olga, Voice Markers of Lexical Access in Mild Cognitive Impairment and Alzheimer's Disease, Current Alzheimer Research 2018; 15 (2) . https://dx.doi.org/10.2174/1567205014666170829112439
DOI https://dx.doi.org/10.2174/1567205014666170829112439 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Alteration of Coagulation in Patients with Thyroid Dysfunction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Prevalence, Incidence, Risk and Protective Factors of Amnestic Mild Cognitive Impairment in the Elderly in Shanghai
Current Alzheimer Research Prevalence and Predictors of Overweight and Obesity in Patients with Pituitary Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile
Current Pharmaceutical Design Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway
Current Alzheimer Research Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases
Mini-Reviews in Medicinal Chemistry The Prevalence, Morbidities, and Treatments of Insomnia
CNS & Neurological Disorders - Drug Targets Cholesterol, Lipids, Amyloid Beta, and Alzheimers
Current Alzheimer Research Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) Conference Report: (13th International Congress on Amino Acids, Peptides and Proteins (ICAPP); Neurobiology Symposium, October 5-7, 2013; Galveston TX, USA.)
CNS & Neurological Disorders - Drug Targets Intracranial Atherosclerotic Stenosis is Related to Post-stroke Cognitive Impairment: A Cross-sectional Study of Minor Stroke
Current Alzheimer Research Difficulties in the Management of Frontal Dementia: Therapeutics Strategies
Letters in Drug Design & Discovery Multifunctional Tacrine Derivatives in Alzheimer’s Disease
Current Topics in Medicinal Chemistry Cognitive Identity in Schizophrenia: Vision, Space, and Body Perception from Prodrome to Syndrome
Current Psychiatry Reviews Potential Role of microRNAs in Cardiovascular Disease: Are They up to Their Hype?
Current Cardiology Reviews Lithium in Psychiatry-The Benefits and Risks Associated with the Lithium Salts Treatment in Affective Disorders
Current Psychopharmacology Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors
Current Pharmaceutical Design